Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Hot Dogs Should Carry Cancer Warning Labels Says US Non Profit Group
A US non-profit organization filed a lawsuit on Wednesday asking a New Jersey county court to force food companies to put labels warning of
generic viagra online
Pregnant Women With H1n1 Flu Should Start Antiviral Treatment As Soon As Possible, While Those Who Are Well Should Be Vaccinated
An Article published Online First (http://www.thelancet.com) and in an upcoming edition of The Lancet shows that pregnant women could be at increased risk for complications from H1N1 flu. Furthermore, the study, from the USA, shows that the rate of hospitalisation for pregnant women is more than four times that of the general population. Pregnant women with H1N1 flu should start antiviral treatment as soon as possible, while those who are well should be vaccinated once a vaccine becomes available. The Article is written by Dr Denise J Jamieson, Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, USA, and colleagues.
News of the day
Swissmedic Grants Debiopharm Marketing Authorisation For Moapar(R), A New Therapeutic Avenue For The Treatment Of Sexual Deviations
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that the Swiss agency for therapeutic products, Swissmedic, has issued a marketing authorisation for Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations. Developed by Debiopharm, Moapar(R) contains a gonadotropin-releasing hormone (GnRH) agonist analogue.
Diagnostics

Merck Seeks European License For Cladribine for relapsing remitting MS

Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes after results of a phase III clinical trial were reported in April at the annual American Academy of Neurology meeting in Seattle Washington. If the application meets all of the regulatory hurdles, it is set to be the first oral disease modifying drug available to people with MS. If no delays are made, cladribine could be available as early as the middle of 2010, which could mean more choice for people with MS. Multiple Scleroris Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009